Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spironolactone improves left atrial function and atrioventricular coupling in patients with resistant hypertension.

The international journal of cardiovascular imaging·2023
Same author

Adverse cardiac remodeling is absent in patients with true controlled resistant hypertension.

Journal of clinical hypertension (Greenwich, Conn.)·2023
Same author

Racial Differences in XO (Xanthine Oxidase) and Mitochondrial DNA Damage-Associated Molecular Patterns in Resistant Hypertension.

Hypertension (Dallas, Tex. : 1979)·2022
Same author

Diastolic function: modeling left ventricular untwisting as a damped harmonic oscillator.

Physiological measurement·2022
Same author

Elucidation of obstructive sleep apnoea related blood pressure surge using a novel continuous beat-to-beat blood pressure monitoring system.

Journal of hypertension·2021
Same author

Spironolactone Reduces Aortic Stiffness in Patients With Resistant Hypertension Independent of Blood Pressure Change.

Journal of the American Heart Association·2021
Same journal

Neural Control of Tissue Perfusion: Emerging Evidence and Beyond.

Current hypertension reports·2026
Same journal

Correction to: Should Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy?

Current hypertension reports·2026
Same journal

Intersection of Pediatric Hypertension and Cardiovascular-Kidney-Metabolic Disease.

Current hypertension reports·2026
Same journal

Combined Aldosterone Synthase and SGLT2 Inhibition: A Recipe for Success in CKD with Uncontrolled Blood Pressure?

Current hypertension reports·2026
Same journal

Leveraging the Electronic Health Record to Identify and Manage Resistant Hypertension.

Current hypertension reports·2026
Same journal

Should Incretin Agonist-Based Brugs be Considered for First Line Antihypertensive Therapy?

Current hypertension reports·2026
See all related articles

Related Experiment Video

Updated: Jun 28, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Resistant hypertension and hyperaldosteronism.

Carolina C Gonzaga1, David A Calhoun

  • 1carolina.gonzaga@ccc.uab.edu

Current Hypertension Reports
|October 31, 2008
PubMed
Summary
This summary is machine-generated.

Resistant hypertension, often linked to primary aldosteronism, requires comprehensive treatment. Effective management includes lifestyle changes, addressing secondary causes like hyperaldosteronism, and utilizing multidrug regimens with diuretics and mineralocorticoid receptor antagonists.

Related Experiment Videos

Last Updated: Jun 28, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Area of Science:

  • Cardiology
  • Nephrology
  • Endocrinology

Background:

  • Resistant hypertension affects 20-30% of patients despite multiple medications.
  • Common contributing factors include hyperaldosteronism, obesity, and sleep apnea.
  • Primary aldosteronism (PA) is prevalent in approximately 20% of resistant hypertension cases.

Purpose of the Study:

  • To highlight the significance of primary aldosteronism in resistant hypertension.
  • To recommend screening protocols for PA in affected patients.
  • To outline comprehensive treatment strategies for resistant hypertension.

Main Methods:

  • Review of clinical trials and studies on resistant hypertension and primary aldosteronism.
  • Discussion of diagnostic methods for PA, including urinary aldosterone and plasma aldosterone/renin activity ratio.
  • Emphasis on a multidrug treatment approach incorporating lifestyle modifications and specific medications.

Main Results:

  • Primary aldosteronism is a frequent secondary cause of resistant hypertension.
  • Screening for PA is recommended for most patients with resistant hypertension.
  • Mineralocorticoid receptor antagonists offer significant benefits in resistant hypertension management.

Conclusions:

  • Accurate diagnosis and treatment of secondary causes, particularly PA, are crucial for managing resistant hypertension.
  • A combination of lifestyle changes, effective multidrug regimens (including diuretics like chlorthalidone), and potentially mineralocorticoid receptor antagonists is key.
  • Early screening and targeted treatment of PA can improve blood pressure control in resistant hypertension patients.